Grace Therapeutics (NASDAQ:GRCE) Stock Rating Lowered by Wall Street Zen

Grace Therapeutics (NASDAQ:GRCE) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

GRCE has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Friday, July 17th. Craig Hallum set a $4.00 target price on Grace Therapeutics in a research report on Friday, April 24th. Finally, TD Cowen cut their target price on Grace Therapeutics from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, April 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.

Grace Therapeutics Price Performance

Grace Therapeutics stock opened at $2.08 on Friday. The company has a market capitalization of $33.84 million, a PE ratio of -4.33 and a beta of 0.39. Grace Therapeutics has a 12-month low of $1.79 and a 12-month high of $5.18. The firm’s fifty day moving average is $2.35 and its 200 day moving average is $3.18.

Grace Therapeutics (NASDAQ:GRCE) last posted its quarterly earnings results on Thursday, June 18th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.17. Sell-side analysts expect that Grace Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Grace Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GRCE. Stratos Wealth Partners LTD. bought a new position in shares of Grace Therapeutics during the 4th quarter worth approximately $39,000. Kestra Private Wealth Services LLC bought a new position in shares of Grace Therapeutics in the first quarter valued at approximately $60,000. SeaCrest Wealth Management LLC bought a new position in shares of Grace Therapeutics in the third quarter valued at approximately $42,000. XTX Topco Ltd bought a new position in shares of Grace Therapeutics in the fourth quarter valued at approximately $106,000. Finally, Pale Fire Capital SE purchased a new stake in shares of Grace Therapeutics during the first quarter valued at approximately $175,000. 6.08% of the stock is owned by institutional investors.

About Grace Therapeutics

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.